Financial Performance - Revenue decreased by 1% to $59.5 million in FY25 compared to FY24[24] - Net Profit After Tax (NPAT) increased by 17% to $10.4 million in FY25 compared to FY24[24] - The company achieved a record quarterly profit before tax of $4.3 million from revenue of $16.8 million during June Q4[24] - Earnings Per Share (EPS) reached 7.4 cents, and a fully franked dividend of 4.5 cents per share was declared[24] Balance Sheet - Cash and cash equivalents increased by 2% to $12.2 million in 2025[25] - Total assets increased by 7% reaching $72.8 million in 2025[25] - Total equity increased by 8% reaching $60.2 million in 2025[25] Acquisitions - The company acquired the remaining 50% of Orbis Mining on 26 July 2024 for $3.91 million upfront consideration[20] - The company acquired 100% of Labfit on 13 December 2024 for $1.16 million upfront consideration[20] Segment Performance - Consumables sales revenue increased by 2% to $19.3 million in FY25[28] - Precious Metals sales revenue remained flat at $21.5 million in FY25[31] - Capital Equipment sales revenue increased by 4% to $22.6 million in FY25[35]

Core Viewpoint - Kewaunee Scientific Corporation (KEQU) has received an upgrade to "Outperform" due to strong acquisition execution, sustained margin improvement, a record backlog providing revenue visibility, and partial insulation from macroeconomic challenges through healthcare exposure [1]. Acquisition Execution & Strategic Fit - The acquisition of Nu Aire, Inc. in November 2024 has resulted in a 30.7% year-over-year increase in domestic segment sales, reaching $179.4 million in fiscal 2025 [2]. - This acquisition has expanded KEQU's product portfolio to include higher-margin products like biological safety cabinets, CO2 incubators, and ultralow freezers, while also establishing new distribution partners in previously underpenetrated markets [3]. - Integration progress has exceeded expectations, creating early cross-selling opportunities and reinforcing KEQU's position as a full-spectrum laboratory solutions provider [3]. Gross Margin Expansion & Profitability Gains - KEQU's gross margin has expanded by 310 basis points to 28.6% in fiscal 2025 from 25.5% in fiscal 2024, driven by Nu Aire's favorable product mix, operational efficiencies, and disciplined cost control, despite incurring $6 million in one-time integration and purchase accounting expenses [4]. - Adjusted EBITDA increased by 28.4% to $26.5 million, representing 10.9% of sales, indicating the company's ability to convert top-line gains into higher operating leverage [5]. - The annuitization of the company's pension obligation in fiscal 2024 has reduced earnings volatility, providing a cleaner base for future margin expansion [5]. Record Backlog & Revenue Visibility - KEQU has a record backlog of $214.6 million at the end of fiscal 2025, up 37.9% from the previous year, providing exceptional near-term revenue visibility, with management expecting 93% of orders to convert into revenues in fiscal 2026 [6]. - The backlog includes diverse end markets such as healthcare, pharmaceuticals, and education, which helps mitigate cyclicality often seen in the broader construction and industrial sectors [6]. - The healthcare and life sciences sectors, enhanced by Nu Aire's capabilities, have shown greater resilience against macroeconomic uncertainty, providing KEQU with a degree of macro immunity [7]. Conclusion - Kewaunee's transformation following the Nu Aire acquisition, along with strong domestic performance, expanding margins, record backlog, and attractive valuation, supports an Outperform rating [10]. - The company is positioned to deliver above-market returns over the next 12 months, with key catalysts including backlog conversion and incremental synergies from the Nu Aire integration [10].

Financial Data and Key Metrics Changes - Sales for the quarter were $983 million, representing a 2% increase in local currency and a 4% increase on a U.S. dollar reported basis [11] - Adjusted EPS for the quarter was $10.9, a 5% increase over the prior year [15] - Gross margin was 59%, a decrease of 70 basis points due to tariff costs and lower volume [13] Business Line Data and Key Metrics Changes - Laboratory sales increased by 1%, while industrial sales increased by 4%, with core industrial up 2% and product inspection up 8% [12] - Food retail sales were flat for the quarter [28] - Service business grew by 4% in the quarter and 5% year-to-date [30] Market Data and Key Metrics Changes - Local currency sales increased by 3% in The Americas, were flat in Europe, and increased by 3% in Asia Rest of the World [12] - Local currency sales in China declined by 2% during the quarter [12] Company Strategy and Development Direction - The company is focused on leveraging its innovative product portfolio and strategic programs to navigate uncertain market conditions [8] - There is an emphasis on capitalizing on onshoring investments and the demand for automation and productivity solutions [27][32] - The company anticipates growth opportunities from the replacement cycle of aging equipment as market conditions stabilize [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in mitigating tariff impacts and expects to fully offset these costs next year [10][20] - The outlook for the second half of the year remains cautious, with expectations of stable demand in China and mixed conditions in the laboratory sector [44] - Management noted that geopolitical tensions and trade disputes continue to create uncertainty in the market [20] Other Important Information - The company expects local currency sales to grow approximately 3% to 4% for the full year 2025 [21] - Adjusted EPS guidance for 2025 is in the range of $10.55 to $10.75, reflecting a growth rate of 3% to 5% [22] - The effective tax rate is expected to remain at 19% for 2025 [24] Q&A Session Summary Question: Impact of Swiss tariffs on EPS guidance - Management indicated that the gross headwind from the Swiss tariffs is approximately $0.40, and they are working on mitigation actions for next year [36][38] Question: Demand visibility in China - Management noted that while there is some stabilization, underlying market conditions remain soft, and they have not factored in potential stimulus [40][45] Question: Strength in product inspection - Management highlighted that new product innovations have led to market share gains and they expect continued growth in this segment [48][51] Question: Service business timing issues - Management explained that timing issues in Q2 were project-related, but they remain optimistic about growth in the second half of the year [75][78] Question: Replacement cycle dynamics - Management discussed pent-up demand for equipment replacement and indicated that while there may not be a snapback, there will be an acceleration as market confidence returns [99][101]

Core Insights - Scientific Industries, Inc. reported a 5% revenue growth in its Benchtop Lab Equipment Operations for Q1 2025, driven by the Genie and Torbal Divisions, with a notable increase in US-based customers [4][5][6] - Overall revenue for the first quarter decreased by 3% due to a significant decline in international sales, which fell by 33% [4][6] - The company secured $1.5 million in equity financing and reported a decreased net loss of $1.78 million, improving from a loss of $2.05 million in the same period last year [5][9] Financial Overview - Net revenues for Q1 2025 totaled $2.41 million, down from $2.48 million in Q1 2024, primarily due to a $182,600 decrease in Bioprocessing Systems Operations revenues [6][17] - Benchtop Laboratory Equipment revenues increased to $2.3 million, a 5% rise compared to $2.2 million in the prior year [5][17] - Bioprocessing Systems Operations revenues decreased by 58% to $133,500 from $316,100 in the previous year [5][17] Profitability Metrics - Gross profit for Q1 2025 was $1.02 million, slightly down from $1.04 million in Q1 2024, with a gross margin of 42.2%, up from 41.9% [7][17] - Operating expenses decreased by 9.7% to $2.83 million, attributed to cost-cutting measures implemented in fiscal 2024 [8][17] - The company reported a basic and diluted loss per share of $0.16, an improvement from $0.20 in the same quarter last year [9][17] Strategic Developments - The company is planning to scale its DOTS platform with the launch of a new optical pH sensor and high-performance liquid injection system in the second half of 2025 [4] - A peer-reviewed publication validated the DOTS Multiparameter platform, confirming its sensitivity and reliability compared to industry standards [4][5]

Core Points - Scientific Industries, Inc. will file a Form 10Q and issue a press release regarding its first quarter financial results for the period ending March 31, 2025, after the market close on May 13, 2025 [1] - A conference call is scheduled for May 14, 2025, at 11:00 AM Eastern Time to discuss the financial results [2] Company Overview - Scientific Industries, Inc. is a life science tool provider that designs, manufactures, and markets laboratory equipment, including the Vortex-Genie 2 Mixer and Torbal balances, as well as bioprocessing systems under the product name DOTS [4] - The company's products are primarily used for research purposes in laboratories across universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies [4] Subsidiary Information - Scientific Bioprocessing, Inc. (SBI), a subsidiary of Scientific Industries, focuses on digitally simplified bioprocessing, offering bioprocess sensors, actuators, and data analytics software to help monitor and control critical process parameters and product quality [5]